PIOTREK
Member
- Awards
- 0
this is a quote from big cat's article:
"The low liver-toxicity is accounted for that the bio-availability of methenolone is carried by a 1-methyl-group, which lessens the need for a carrier attachment such as a 17-alpha-akylated group, the main culprit in steroid-related liver afflictions."
my question is, why has this alternate method (1-methly-group modification) not been employed in more drugs/once legal prosteroids?
"The low liver-toxicity is accounted for that the bio-availability of methenolone is carried by a 1-methyl-group, which lessens the need for a carrier attachment such as a 17-alpha-akylated group, the main culprit in steroid-related liver afflictions."
my question is, why has this alternate method (1-methly-group modification) not been employed in more drugs/once legal prosteroids?